• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Mannkind Corporation - Articles and news items

Afrezza® (insulin human) Inhalation Powder

Sanofi and MannKind announce Afrezza®, the only inhaled insulin, now available in the U.S.

Industry news / 3 February 2015 / Sanofi / MannKind Corporation

Sanofi and MannKind Corporation announced today that Afrezza® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by prescription in U.S. retail pharmacies nationwide. Afrezza is approved by the U.S. Food and Drug Administration to control high blood sugar in adults with type 1 and type 2 diabetes…


Sanofi and MannKind announce global licensing agreement for Afrezza® (insulin human) rapid-acting inhaled insulin

Industry news / 12 August 2014 / Sanofi

Sanofi and MannKind Corporation announced that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza® (insulin human) Inhalation Powder…

Phenomenex Logo


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +